Atlas Trials

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Clinical trial NCT04447118 · COMPLETED

Trial details

NCT number
NCT04447118
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Non-squamous NSCLCHER2 Exon 20 Mutation
Start date
2020-09-11
Primary completion
2023-06-02
Enrollment
151

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.